William Blair Starts Alcon Inc. (ALC) at Market Perform

William Blair analyst Steven Lichtman initiates coverage on Alcon Inc. (NYSE: ALC) with a Market Perform rating.

The analyst comments "Thesis. We are initiating coverage of Alcon with a Market Perform rating. Alcon is a multinational eye care company that operates through two core segments: surgical and vision care. Over the past two years, Alcon has been aggressive in driving top-line growth both internally (increased R&D spend) and externally (several announced tuck-in acquisitions). We believe a premium is warranted given the company’s full pipeline, but with the stock already trading at a roughly 25% premium (slightly above historical) based on a 2026 P/E multiple, we look for potential upside drivers to estimates, including mix upgrade potential in Consumables and performance of Alcon’s dry eye disease drug, TRYPTYR."

For an analyst ratings summary and ratings history on Alcon Inc. click here. For more ratings news on Alcon Inc. click here.

Shares of Alcon Inc. closed at $81.15 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'